Swisstom: third round of financing concluded and first product launched

Schlieren, July 17, 2014

The med-tech start-up Swisstom has celebrated its market debut and successfully completed the third round of financing. Lead investor Zühlke Ventures continues to be actively involved in the development of the young company.

This spring, Swisstom received CE approval for its first product: Swisstom BB2, a textile vest which monitors the lung function of ICU patients undergoing mechanical ventilation. It is equipped with active electrodes which measure breathing in different lung regions and convert the data into real-time images. The product has already been launched on the European market. The successful completion of the third round of financing now makes concerted market development possible.

Leading med-tech company joins as investor
The new product, which is perfectly tailored to the needs of patients, doctors and nursing staff, and its outstanding technology convinced a leading global medical technology company to join Swisstom as a strategic investor. Together with existing investors, the financing round raised a total of 4.4 million francs. As a result, Swisstom has more capital at its disposal for the first phase of the launch than originally planned. Over the last three years, Swisstom has acquired total capital of 12 million francs.

Strategic partnerships
Swisstom succeeded in winning the leading European med-tech company, Maquet, as a partner for the distribution of the new product. In addition, Salvia and Heinen + Löwenstein have integrated the Swisstom technology into their newest respirator, "elisa 800 VIT". This makes the two companies, which specialize in the manufacture and distribution of ventilators, the first in the world to offer a fully integrated electrical impedance tomography (EIT) system. Other strategic integrators are already under contract. "Thanks to its great potential for innovation, Swisstom will not only strengthen its market position but also continue to expand its product range and open up further areas of application", says Martin Rutishauser of Zühlke Ventures confidently. "This will enable the company to secure its leadership in the field of EIT applications in medical technology over the long term".

For more information please visit

Our contact

Photo: Mr Martin Rutishauser

Martin Rutishauser

Member of the Board & Partner